NCT01909479

A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting hGH Product (MOD-4023) In Adult Subjects With Growth Hormone Deficiency

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 202 (actual)
• Sponsor: OPKO Health, Inc. · Industry
• Sex: All
• Age: 23 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).

Conditions

• Adult Growth Hormone Deficiency

Interventions

Type	Name	Description
DRUG	MOD-4023	Individualized once weekly dose of MOD-4023
OTHER	Placebo	Once weekly administration of placebo

Timeline

• Start date: 2013-06-01
• Primary completion: 2016-08-01
• Completion: 2018-08-01
• First posted: 2013-07-26
• Last updated: 2022-08-12
• Results posted: 2022-08-12

Locations

1 site across 1 country: Israel